LONDON, Sept. 29, 2025 /PRNewswire/ -- QInscribe, a new medical writing services brand, officially launches today. Offering generative Artificial Intelligence (AI) driven regulatory writing, scientific writing and clinical trial transparency services. QInscribe aims to disrupt the medical writing space with generating high quality regulatory documents at record breaking production times with advanced AI-supported workflows.
With pharmaceutical and biotechnology companies under increasing pressure to streamline regulatory submissions and improve document consistency, QInscribe steps into the market with a specialised model of generating first draft regulatory documents with AI processes. This unique approach is built for scale and enables QInscribe to support large volume and tight turnaround request.
"Medical writing can benefit from the AI revolution that is reshaping industries worldwide. It can still uphold the highest quality standards that you would expect, but in a fraction of the time," said Amol Hule, Associate Director of Medical Writing at QInscribe. "We combine specialist human insight from a team of experienced medical writers with AI-enabled efficiencies to ensure every deliverable is accurate, consistent, and submission-ready."
Whereas a draft Clinical Study Report traditionally used to take approximately 50-100 hours to generate, this can now be done in as little as 5 hours. This efficiency will be passed on to QInscribe's customers. Qinscribe also provides a range of services across regulatory medical writing.
About QInscribe
QInscribe is a specialist medical writing provider who partners with biopharmaceutical companies of all sizes, from emerging biotech to established global sponsors, delivering regulatory, scientific, and transparency-focused documents with accuracy, speed, and strategic insight. Through a unique combination of expert-led services and AI-supported workflows, QInscribe empowers clinical teams to meet global documentation demands with confidence.
www.qinscribe.com
Logo: https://mma.prnewswire.com/media/2782303/QInscribe_Logo.jpg
Media Contact:
Sarah Ball
Communications Lead
info@qinscribe.com
+44?(0)1462 440 084
View original content:https://www.prnewswire.co.uk/news-releases/new-medical-writing-service-qinscribe-reduces-the-time-to-generate-a-draft-clinical-study-report-csr-by-90-with-generative-ai-solution-302568126.html
